Novo Nordisk and Eli Lilly are competing in the obesity drug market with their GLP-1 pills, Wegovy and Foundayo, respectively. Both companies are preparing for Medicare to cover these drugs for weight loss at $50 per month starting July 1, which could expand access to millions of seniors. Novo Nordisk has seen over 3 million prescriptions for Wegovy since its U.S. launch five months ago, while Lilly reports rapidly increasing prescriptions of Foundayo. The companies emphasize different benefits: Novo highlights additional cardiovascular and organ protection, while Lilly promotes convenience and ease of use. Both are also developing next-generation obesity drugs, with Lilly advancing retatrutide and Novo working on CagriSema, aiming to maintain leadership in the growing obesity treatment market.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
